- 04
Performance evaluation:
cfDNA - Cell-free DNA (cfDNA) is DNA that circulates freely in blood and other body fluids, released from cells. First recognized in 1977, cfDNA levels were found to be higher in cancer patients than in healthy individuals. Since then, cfDNA has been widely used in diagnostics for both cancer and prenatal testing. In cancer, cfDNA helps track mutations and assess tumor heterogeneity. In prenatal testing, fetal cfDNA in maternal blood is analyzed to detect genetic abnormalities, providing a non-invasive alternative to traditional diagnostic methods.
Despite its utility, a major challenge is the low yield of cfDNA, which can limit downstream applications. To overcome this, the Exgene™ cfDNA SV mini was developed, optimized to efficiently isolate cfDNA without the need for organic solvents or pre-treatment.
This study aims to evaluate the performance of the Exgene™ cfDNA SV mini by comparing it with a competitor's equivalent kit in cancer patient plasma and serum samples.